Back to School: How biopharma can reboot drug development. Access exclusive analysis here
KOSN and Roche (SWX:ROG) will end a 2002 deal to develop and commercialize epothilone compounds to
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury